Business Wire

Kymeta Launches KĀLO™ Trek Across America


Redmond-based Kymeta—the communications company making good on the promise of global mobile connectivity—set out on a two-week trek across America in its connected Toyota RAV4 to provide a rigorous, real-world proving ground for its widely anticipated KĀLO™ internet service. KĀLO services will deliver a new mobile satellite internet service that will make mobile high-throughput internet access available and easy to buy. The KĀLO Trek Across America will begin in Washington, D.C. and wind through the country, covering over 7,000 miles, and culminating in a homecoming event at the Kymeta campus in Washington state on November 27.

Powered by the IntelsatOne® Flex network, Kymeta KĀLO services will provide high-bandwidth mobile satellite internet access to industries that require connectivity on the move like military, news reporting, first responders, construction, trains, buses and more. KĀLO services, when paired with Kymeta™ KyWay™ terminals and mTennau7 ASMs, will connect places and fixed and mobile platforms that have traditionally had limited or no connectivity at all.

“Kymeta is taking its connected car across the country to put the network through the paces,” said Dushyant Sukhija, SVP and General Manager, KĀLO Business Unit, Kymeta. “When launched, KĀLO mobile internet services will mark a revolutionary change in the way satellite services are purchased and supplied, making it as simple as purchasing a cell phone plan. The launch of Kymeta KĀLO services will usher in changes in the way businesses get work done: on the move, from everyday vehicles, in even the most difficult to reach industries and areas of the world.”

The KĀLO Trek Across America tells another important story: the possibility of a truly connected car is now a reality. Kymeta’s Toyota RAV4 will remain connected throughout its U.S. journey, conducting live streams and updates from the road. “As innovations in satellite connectivity come to market, such as our Intelsat EpicNG high-throughput satellites, we are unlocking new applications. Industries recognize that connected cars and other vehicles will enable new services and opportunities for increased efficiency; traditional networks can’t support that growth today,” said Mark Rasmussen, VP and General Manager, Mobility, Intelsat. “Leveraging our global IntelsatOne Flex network, our partnership with Kymeta will bring KĀLO internet services to every corner of the U.S., and eventually every region of the world. This plan aligns to our goal: make connectivity accessible to everyone, everything, everywhere, at any time. Kymeta KĀLO services are proof that connectivity can reach every industry, large and small, and be used for any application, no matter where you are, especially while you’re on the move.”

For a map of the KĀLO Trek Across America destinations, and to follow along as the team gives updates on the route home, visit KĀLO Trek online.

About Kymeta

What’s the missing link to connecting billions of people to high-speed mobile access? Antennas. And Kymeta offers the world’s only commercially viable electronically scanning satellite antennas and terminals. Kymeta antennas and terminals deliver high-throughput communications for land, sea and air, making mobile connectivity as available as a view of the sky. Plus, the world’s largest satellite operator, Intelsat, has joined forces with Kymeta to deliver KĀLO™ global access services that combine with Kymeta antennas and terminals to provide revolutionary mobile connectivity. Without Kymeta mTenna™ technology, connecting and staying connected to all those new satellites while on the move will be difficult, if not impossible.

If it moves, Kymeta will keep it connected. Anywhere.

For more information, visit and

Contact information

Business Inquiries for Kymeta:
Kymeta Corporation
Lisa Dreher, +1 425-658-8724
Director of Marketing
Media Inquiries for Kymeta:
The Summit Group
Amy Oliver, +1 801-990-1185
Mobile: +1 801-783-9067
PR/Content Manager

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Elliott Welcomes Imminent Bezeq Board Overhaul and New Era for Strong Independent Governance23.3.2018 19:05Tiedote

Elliott Advisors (UK) Limited (“Elliott”), which advises funds which collectively hold a significant economic interest in Bezeq The Israeli Telecommunication Corporation Ltd. (“Bezeq” or the “Company”), welcomes the proposed governance reforms announced by Bezeq last night. In its initial letter to Bezeq Interim Chairman David Granot, dated January 16, 2018, Elliott outlined the urgent need to address the Company’s serious corporate governance issues, and called for changes at the Board level that result in “the right mixture of expertise, independence and integrity for the future.” Elliott stated then, and reiterates now, its belief that “there is significant value to be unlocked if the right steps are taken to improve its corporate governance.” Bezeq has strong business fundamentals, an exemplary workforce, and great potential. Following yesterday’s announcement, Elliott highlights the changes that have occurred since January 16th. Taken together, these amount to a revolution in the

Clovis Oncology Initiates Early Access Program for Rucaparib as Treatment and as Maintenance Therapy in Recurrent Ovarian Cancer in Europe23.3.2018 15:52Tiedote

Clovis Oncology, Inc. (NASDAQ:CLVS) today announced the initiation of an early access program in Europe for rucaparib for treatment and as maintenance therapy in recurrent ovarian cancer. The program will be overseen and implemented by Caligor Coghlan, which specializes in early access to medicines. The program, to be known as the Rucaparib Access Program (RAP), will enable participation from certain countries in Europe, where permitted by applicable rules, procedures and regulatory authorities. The RAP protocol allows for rucaparib treatment of an individual patient with third-line or greater BRCA mutant epithelial, fallopian tube, or primary peritoneal ovarian cancer who has platinum-sensitive disease and is unable to tolerate further platinum-based chemotherapy or has platinum-resistant disease and needs treatment with single agent rucaparib. The RAP protocol will also provide access to rucaparib for maintenance therapy of an individual patient with recurrent epithelial ovarian, fal

CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets23.3.2018 15:50Tiedote

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union’s (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a conditional marketing authorization for Rubraca as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy. The European Marketing Authorization application for the treatment indication was based on objective response rate and duration of response results from two multicenter, single-arm, open-label clinical trials, Study 10 and ARIEL2, in women with advanced BRCA mutant ovarian cancer who had progressed after two or more prior chemotherapies. “The recommendation

Janssen Announces Positive CHMP Opinion for JULUCATM▼ (dolutegravir/rilpivirine)23.3.2018 15:46Tiedote

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending marketing authorisation for JULUCA™ (dolutegravir 50mg [ViiV Healthcare UK Ltd]/rilpivirine 25mg [Janssen Sciences Ireland UC]). Dolutegravir/rilpivirine is a single-pill, two-drug regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 c/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase strand transfer inhibitor (INSTI).1 “We are delighted to be one step closer to bringing JULUCA™ to people living with HIV in Europe,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, LLC. “Building on our 25-year c

Aitheon Executives Educate World Leaders on Benefits, Challenges of AI at the Annual World Government Summit in Dubai23.3.2018 15:00Tiedote

Aitheon, makers of the world’s first blockchain-powered platform to solve real problems by integrating AI, robotics, IoT, human specialists and cryptocurrency, announced today that executives from the company held a series of high-level briefings with world leaders at the Annual World Government Summit in Dubai. Briefings covered the benefits and challenges of AI, and revolutionary new solutions to world challenges made possible by transformative new technologies. (Read the full release at This press release features multimedia. View the full release here: Aitheon founder and CEO, Andrew Archer, and Chief Strategy Officer, Ryan Burleson, were invited to brief leaders at the Summit by Cyrus Hodes, Co-founder and Director of the AI Initiative, an undertaking of the Future Society at Harvard University’s Kennedy School. Archer and Burleson addressed a variety of AI-related topics, including the impact of AI on

ViiV Healthcare Gains CHMP Positive Opinion for Juluca (dolutegravir/rilpivirine) in Europe23.3.2018 14:27Tiedote

ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a Positive Opinion recommending marketing authorisation for Juluca (dolutegravir/rilpivirine) for the treatment of HIV infection in adults who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor. The 2-drug regimen comprises dolutegravir 50mg (ViiV Healthcare) and rilpivirine 25mg (Janssen Sciences Ireland UC). Deborah Waterhouse, Chief Executive Officer at ViiV Healthcare commented: “Today is an important milestone for people living with HIV in Europe. It takes us a step closer to offering the first, single-pill, 2-drug regi

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme